Small biotechs shoulder the burdens of an uncertain biopharma sector
Funding troubles and innovation responsibilities are falling more heavily on emerging biotechs under strain from US developments.

Funding troubles and innovation responsibilities are falling more heavily on emerging biotechs under strain from US developments.
AstraZeneca, Tempus and Pathos will develop an AI-driven foundational model to develop therapeutics in oncology.
The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of treatment paradigms,...
Eli Lilly and BigHat Biosciences ink AI antibody discovery deal
3 reasons why biotechs preparing for launch need a compliant content foundation
Google-backed Isomorphic Labs raises $600m to advance AI drug discovery
EU Health Data Space strikes a chord in EU harmonisation plans